Related Experiment Video

Updated: Aug 8, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Bioreductive drugs for cancer therapy: the search for tumor specificity

G E Adams1, I J Stratford

  • 1MRC Radiobiology Unit, Chilton, Didcot, Oxfordshire, UK.

International Journal of Radiation Oncology, Biology, Physics
|May 15, 1994
PubMed

Insights

This study compares bioreductive drugs, exploring tumor hypoxia enhancement with photodynamic therapy (PDT) and nitric oxide (NO) modulation for improved cancer treatment strategies.

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Bioreductive drugs offer targeted cancer therapy by exploiting tumor microenvironment characteristics.
  • Heterocyclic nitro compounds, N-oxides, and quinones represent key classes of bioreductive agents.
  • Tumor hypoxia is a critical factor influencing the efficacy of bioreductive therapies.

Purpose of the Study:

  • To compare the activity of different bioreductive drug classes.
  • To explore strategies for potentiating bioreductive drug efficacy, including tumor hypoxia enhancement and nitric oxide (NO) modulation.
  • To outline future directions for novel bioreductive drug development.

Main Methods:

  • Comparative analysis of bioreductive drug classes (heterocyclic nitro compounds, N-oxides, quinones).
  • Investigation of photodynamic therapy (PDT) in combination with RSU-1069 to increase tumor hypoxia.
  • Utilizing 31P magnetic resonance spectroscopy to assess therapeutic effectiveness.
  • Modulation of nitric oxide (NO) levels using NO-synthase inhibitors like nitro-L-arginine.
  • Analysis of reductase enzyme expression in the tumor microenvironment.

Main Results:

  • Summarized characteristics of RB-6145, tirapazamine, and E09.
  • Demonstrated potential of combining PDT with RSU-1069 to enhance bioreductive drug activity.
  • Showcased the impact of NO modulation on tumor physiology, indicating therapeutic promise.
  • Highlighted the role of reductase enzyme levels in heterogeneous tumor microenvironments.

Conclusions:

  • Bioreductive drugs, particularly when combined with strategies to enhance tumor hypoxia and modulate NO levels, show significant therapeutic potential.
  • Further research into reductase enzyme expression is crucial for optimizing bioreductive therapies in diverse tumor settings.
  • Development of novel bioreductive agents and combination therapies holds promise for advancing cancer treatment.

More Related Videos

Assessing Specificity of Anticancer Drugs In Vitro09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Related Concept Videos

Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.